H Bartelink
Overview
Explore the profile of H Bartelink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
3151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bosma S, van der Leij F, van Werkhoven E, Bartelink H, Wesseling J, Linn S, et al.
Breast Cancer Res Treat
. 2016 Mar;
156(2):391-400.
PMID: 27008183
The purpose of this study was to study the impact of changes in clinical practice on outcome in patients treated with breast-conserving therapy (BCT) over a period of 28 years....
2.
Drukker C, Elias S, Nijenhuis M, Wesseling J, Bartelink H, Elkhuizen P, et al.
Breast Cancer Res Treat
. 2014 Nov;
148(3):599-613.
PMID: 25414025
The 70-gene signature (MammaPrint) has been developed to predict the risk of distant metastases in breast cancer and select those patients who may benefit from adjuvant treatment. Given the strong...
3.
Immink J, Putter H, Bartelink H, Cardoso J, Cardoso M, van der Hulst-Vijgen M, et al.
Ann Oncol
. 2012 Apr;
23(10):2591-2598.
PMID: 22499858
Background: In breast cancer treated with breast-conserving radiotherapy, the influence of the boost dose on cosmetic outcome after long-term follow-up is unknown. Patients And Methods: We included 348 patients participating...
4.
Tanis E, van de Velde C, Bartelink H, van de Vijver M, Putter H, van der Hage J
Eur J Cancer
. 2012 Mar;
48(12):1751-6.
PMID: 22446021
Introduction: Locoregional recurrence (LRR) after breast-conserving therapy is a well-known independent risk factor associated with unfavourable long-term outcome. Controversy exists concerning the prognostic impact of a LRR after a very...
5.
van Nes J, Putter H, van Hezewijk M, Hille E, Bartelink H, Collette L, et al.
Eur J Surg Oncol
. 2010 Jun;
36(7):617-24.
PMID: 20558026
Aims: After treatment, early breast cancer patients undergo follow-up according to standard regimens. After the first year, the main goal is particularly to detect locoregional recurrences (LRR). Our aim was...
6.
de Bock G, Putter H, Bonnema J, van der Hage J, Bartelink H, van de Velde C
Breast Cancer Res Treat
. 2009 Jan;
117(2):401-8.
PMID: 19148746
To study whether the effects of prognostic factors associated with the occurrence of distant metastases (DM) at primary diagnosis change after the incidence of loco-regional recurrences (LRR) among women treated...
7.
Pengel K, Loo C, Teertstra H, Muller S, Wesseling J, Peterse J, et al.
Breast Cancer Res Treat
. 2008 Sep;
116(1):161-9.
PMID: 18807269
Aim: To assess whether preoperative contrast-enhanced magnetic resonance imaging (MRI) of the breast influences the rate of incomplete tumor excision. Methods: In a cohort of 349 women with invasive breast...
8.
Poortmans P, Collette L, Bartelink H, Struikmans H, Van den Bogaert W, Fourquet A, et al.
Cancer Radiother
. 2008 Sep;
12(6-7):565-70.
PMID: 18760649
Purpose: To investigate the impact of the boost dose to the primary tumour bed in the framework of breast conserving therapy on local control, cosmetic results, fibrosis and overall survival...
9.
Boyle P, Anderson B, Andersson L, Ariyaratne Y, Auleley G, Barbacid M, et al.
Ann Oncol
. 2008 Aug;
19(9):1519-21.
PMID: 18723552
No abstract available.
10.